Coherus BioSciences, Inc.

CHRS

US19249H1032

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-10 pm EST			5-day change	1st Jan Change
1.470 ^USD	-2.65%		-11.45%	+6.52%

Dec. 20	Coherus BioSciences, Inc.(NasdaqGM:CHRS) dropped from NASDAQ Biotechnology Index	CI
Dec. 18	Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025	CI

Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million

December 03, 2024 at 07:48 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Coherus BioSciences, Inc.

Coherus BioSciences, Inc.(NasdaqGM:CHRS) dropped from NASDAQ Biotechnology Index	Dec. 19	CI
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025	Dec. 18	CI
Coherus BioSciences, Inc. Announces Resignation of Kimberly J. Tzoumakas from the Board of Directors, Effective December 31, 2024	Dec. 04	CI
Coherus BioSciences, Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 03:15 PM	Dec. 03
Sector Update: Health Care Stocks Decline Premarket Tuesday	Dec. 03	MT
Sector Update: Health Care	Dec. 03	MT
Coherus BioSciences, Inc. - Special Call	Dec. 03
Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million	Dec. 03	MT
Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. for $560 million.	Dec. 02	CI
Coherus BioSciences, Inc., Q3 2024 Earnings Call, Nov 06, 2024	Nov. 06
Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q3 Loss $-0.01	Nov. 06	MT
Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q3 Revenue $70.8M	Nov. 06	MT
Coherus BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 06	CI
Codexis, Inc. Appoints Georgia Erbez as Chief Financial Officer	24-10-02	CI
Top Midday Decliners	24-09-16	MT
Sector Update: Health Care Stocks Rise Late Afternoon	24-08-16	MT
Sector Update: Health Care	24-08-16	MT
Coherus BioSciences Shares Decline After Downgrade From UBS	24-08-16	MT
UBS Downgrades Coherus BioSciences to Neutral From Buy, Adjusts Price Target to $1.50 From $4	24-08-16	MT
Coherus BioSciences, Inc., Q2 2024 Earnings Call, Aug 08, 2024	24-08-08
Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q2 Revenue $65M, vs. Street Est of $56.2M	24-08-08	MT
Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q2 Loss $-0.14, vs. Street Est of $-0.26	24-08-08	MT
Coherus BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-08	CI
Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer	24-07-15	CI
Coherus BioSciences Grants Apotex License to Distribute Toripalimab in Canada	24-07-02	MT

Chart Coherus BioSciences, Inc.

Duration

Period

CHRS: Dynamic Chart

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Companyâs immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.

Employees

235

Sector

Biotechnology & Medical Research

Calendar

2025-01-13 - JP Morgan Healthcare Conference

More about the company